about
Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.Deciphering the ovarian cancer ascites fluid peptidome.Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1Fascin-1 is a novel biomarker of aggressiveness in some carcinomas.CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancerActivated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serumStrategies for discovering novel cancer biomarkers through utilization of emerging technologies.Tissue culture-based breast cancer biomarker discovery platform.Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade.Nipple aspirate fluid proteome of healthy females and patients with breast cancer.Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets.False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines.Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.Accuracy of testosterone concentrations in compounded testosterone products.Genomic profiling for copy number changes in plasma of ovarian cancer patients - a new era for cancer diagnostics?Major milestones in translational oncology.Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer.Urinary adenosine excretion in type 1 diabetes.A patient with monoclonal gammopathy-related nephrotic syndrome revealed no electrophoretic "nephrotic pattern" or skewed free light chain ratio.Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids.The Use of Targeted Therapies for Precision Medicine in Oncology.Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics.Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays“Product Ion Monitoring” Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-TrapProteomic and Genomic Technologies for Biomarker Discovery: Where Are the Biomarkers?Analytical evaluation of the VITROS® 5600 Integrated System in a pediatric setting and determination of pediatric reference intervalsPediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas® 6000 analyzer—A CALIPER pilot studyValidating urinary measurement of beta-2-microglobulin with a Roche reagent kit designed for serum measurementsEmerging role of clinical mass spectrometry in pathology
P50
Q33628868-18BB0E6A-1077-486B-83B0-7F43B7CE7D5AQ33786098-A1B9A327-9FA7-4025-AC52-791A61D17E61Q34033606-6E564FD7-5E1B-431E-9879-44E3FBECC0ECQ34501478-184C22EF-BF3F-4B57-9C8F-9219437D1378Q35053898-CE2B1478-4992-4A95-9A5A-F54C50066C60Q36766973-132EF0BB-F73F-411C-BEBA-7C797A34B502Q37074010-FB3E2C45-2D30-4AFA-BE2D-C2753999DC91Q37095851-854623CF-30A8-415A-9A4C-4EB3BD9C5FFAQ37142875-778A0E4E-D848-44C9-8FC5-3CBE60B7656CQ37154428-A5ADF0F3-9323-4B33-9639-A7797FA469A1Q37187946-A1072B4E-4610-45F7-8838-46C00CBCCA58Q37241749-66A18BAD-CF0B-47CA-9BF4-DB90FA74604DQ37246978-A99D2924-F545-4FFF-8B88-DC5F5635F3C3Q37667085-F7BA4437-9269-49A6-BBA7-F690C60A5A15Q37728847-202D3D87-4108-452B-AAC7-94124C46AFF6Q38052927-21E4B279-7E5A-4AE4-BD3A-A97990465804Q38506984-824EFA8B-9076-4AA9-9439-49BDBCD6310FQ38515764-E7347791-1C72-43CD-909F-FC9F1DCC323CQ39085603-F4B5177C-50CE-4924-88D7-2BE4465F2F1EQ40067580-25C2038D-6699-4251-8BFF-F0BEE7CCB06AQ41009650-A846C818-9965-46C3-9735-B0742C0B2E57Q41746040-A3D7A4F3-382F-43A2-A441-DA00DF9D0BCAQ42367374-90E5C1D1-1858-4BC3-A56A-8C05A628F660Q42398020-231FBCA8-52CC-471C-9982-F8C49267837AQ47156375-C3DF5A2C-F649-4810-BE54-28295484283BQ50746947-CD6EC9AE-4392-43EA-8692-0EAE455BD487Q50908211-975F0335-74C9-426C-8551-E321A4BB9D49Q50934477-A0FE91C8-6447-4E66-8905-629583616115Q51581743-417D90F8-0D46-4BBF-8236-FC31C4A47FADQ54060543-059C5C11-DB27-4665-B241-ADC98442ACBCQ55256135-EBCE6440-3480-4E51-A29C-583CA507337CQ57941143-329B774F-8242-4346-A20E-18544E67AF99Q57941273-F000F7C5-3BA1-446E-B1DC-553CA7F769B7Q57941916-3BD707B8-0961-439C-AE83-EF294A511E7FQ58543156-AF9AFCC3-24A5-4106-A20A-6665693F523EQ58543180-6D61D2D0-52FF-4CF6-8F39-1B52CBE82801Q84539626-8DDACB96-82EB-4F13-A21A-49F413E73326Q91129104-4D572D56-F620-41D5-88AE-11B047F3922D
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-5610-873X
@en
name
Vathany Kulasingam
@ast
Vathany Kulasingam
@en
Vathany Kulasingam
@es
Vathany Kulasingam
@nl
type
label
Vathany Kulasingam
@ast
Vathany Kulasingam
@en
Vathany Kulasingam
@es
Vathany Kulasingam
@nl
prefLabel
Vathany Kulasingam
@ast
Vathany Kulasingam
@en
Vathany Kulasingam
@es
Vathany Kulasingam
@nl
P106
P1153
22835094700
P31
P496
0000-0001-5610-873X